Pfizer

SLE Flares Post COVID-19 Vaccine

A study in Japan analyzed the association between mRNA Covid-19 vaccination and medium-term SLE flare-ups. At 30 days after completion of a primary series, the rate of mild or moderate SLE flares was 20.3% within the vaccinated group, versus 23.3% in the unvaccinated group. Flare rates at 60 and 90 days were similar between both groups. 

Read More »

IgG Antibody Responses Across 3 Doses of mRNA Vaccines

A study published in the Journal of Autoimmunity evaluated the immune response of Pfizer and Moderna’s mRNA COVID-19 vaccines in participants with autoimmune systemic diseases. In total, serum samples from 244 AD patients were collected 2-4 weeks and six months after their first vaccine cycle, and 2-4 weeks following their booster dose; 502 people from the general population were used as a control group.

Read More »

Vaccine Efficacy in SLE Patients Across Multiple Variants

A new study investigated vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, in SLE patients. This is one of the first studies on vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, especially in an autoimmune disease patient cohort.

Read More »